Native Labs
Native Labs helps cell and gene therapy manufacturers speed product release and improve quality by turning production data into actionable decisions. It provides an AI-driven operating system comprising a Process Prediction Engine, Bioreactor Control System, and Real-Time Quality Control Release to automate deviations, CAPAs, RCAs, and change controls. The platform integrates with QMS, LIMS, MES, ELN, PAT, MRP, CTMS and EHS systems and uses in-house AI agents and proprietary datasets to build organization-specific intelligent quality models. Native Labs is an enterprise-secure B2B SaaS solution targeting biopharma and biotech manufacturers, designed for rapid deployment to unlock capacity and improve traceability across sites.
Native Labs
Native Labs helps cell and gene therapy manufacturers speed product release and improve quality by turning production data into actionable decisions. It provides an AI-driven operating system comprising a Process Prediction Engine, Bioreactor Control System, and Real-Time Quality Control Release to automate deviations, CAPAs, RCAs, and change controls. The platform integrates with QMS, LIMS, MES, ELN, PAT, MRP, CTMS and EHS systems and uses in-house AI agents and proprietary datasets to build organization-specific intelligent quality models. Native Labs is an enterprise-secure B2B SaaS solution targeting biopharma and biotech manufacturers, designed for rapid deployment to unlock capacity and improve traceability across sites.
TL;DR
Founded: 2023
Headquarters: Ilford / London, United Kingdom
Product: AI-driven Quality Operating System for biomanufacturing
Focus customers: Cell & gene therapy and biologics manufacturers
Notable investor: Zinc
Company Overview
Problem Domain
Quality control, release automation, root-cause analysis, and data unification for biomanufacturing
Founded
2023
Industry
Biotechnology
Tech Stack
Funding Track Record
201,460
Investor Signal
“Zinc listed as an investor”